{"activeTab":"SOL2ODcbaDI1CazQRbRS","articleCategories":[{"data":{"createdAt":{"_type":"Date","value":"Thu Jul 07 2022 16:34:53 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"new-in-myeloma","sectionConfig":{"news":{"description":"Our Treatment Advances articles cover treatment option updates, new combinations of treatments, FDA approval news, and more.","metaDescription":"It's important for patients to stay up-to-speed on advancements in their cancer because the treatment options are rapidly changing.","metaTitle":"Treatment Advances - HealthTree Foundation","order":1,"tileOrder":1,"type":"LARGE_TILE"}},"sections":["NEWS"],"slug":"treatment-advances","status":"ACTIVE","title":"Treatment Advances","updatedAt":{"_type":"Date","value":"Fri Apr 12 2024 20:21:03 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/haqKTOi9lG4MNU3rNLG6"},"snapshot":{"exists":true,"id":"haqKTOi9lG4MNU3rNLG6","ref":{"_type":"DocumentReference","path":"apps/community/categories/haqKTOi9lG4MNU3rNLG6"}}},{"data":{"createdAt":{"_type":"Date","value":"Sat Jul 30 2022 16:56:14 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"fitness","sectionConfig":{"events":{"description":"Our Navigating Your Health events help you manage your wellness through diet, fitness, side effect management, survivorship, and life hacks that can improve your quality of life.","metaDescription":"Events you can join designed for navigating your health such as infection prevention, battling disparities, and survivorship.","metaTitle":"Navigating Your Health Events - HealthTree","order":1},"news":{"description":"Our Navigating Your Health articles can help you proactively take control of your health through wellness news, financial updates, healthy recipes, and more.","metaDescription":"Learn tips related to your overall wellness, including your mental, physical, and emotional health.","metaTitle":"Navigating Your Health - HealthTree Foundation","order":2},"podcasts":{"order":7,"status":"DRAFT"}},"sections":["EVENTS","NEWS"],"slug":"navigating-your-health","status":"ACTIVE","title":"Navigating Your Health","updatedAt":{"_type":"Date","value":"Thu Apr 25 2024 18:37:49 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"snapshot":{"exists":true,"id":"hn1DyzeAyX6tgl3gxSDx","ref":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"}}},{"data":{"createdAt":{"_type":"Date","value":"Thu Jul 07 2022 16:34:03 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"myeloma-basics","sectionConfig":{"news":{"description":"Our Core Education articles help you understand your cancer so you are equipped to find a good care team, ask appropriate questions, and become your own best advocate.","metaDescription":"Learn 101 Education to help you know more about your cancer, what tests and treatments are available to you, and more.","metaTitle":"Core Education - HealthTree Foundation","order":3,"tileOrder":3,"type":"LARGE_TILE"}},"sections":["NEWS"],"slug":"core-education","status":"ACTIVE","title":"Core Education","updatedAt":{"_type":"Date","value":"Fri Apr 12 2024 20:21:23 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/MB3xw38fuKkx0LdszsrL"},"snapshot":{"exists":true,"id":"MB3xw38fuKkx0LdszsrL","ref":{"_type":"DocumentReference","path":"apps/community/categories/MB3xw38fuKkx0LdszsrL"}}},{"data":{"createdAt":{"_type":"Date","value":"Wed Jan 04 2023 22:59:47 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"patient-stories","sectionConfig":{"news":{"description":"Our Patient Stories articles contain patient and caregiver experiences, along with their advice for others going through similar circumstances.","metaDescription":"Read patient stories to learn about other’s experiences and what advice they have for people going through similar circumstances.","metaTitle":"Patient Stories - HealthTree Foundation","order":4,"tileOrder":1,"type":"SMALL_TILE"}},"sections":["NEWS"],"slug":"patient-stories","status":"ACTIVE","title":"Patient Stories","updatedAt":{"_type":"Date","value":"Thu Apr 25 2024 18:37:43 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/19hxT6XALz8ds00eORms"},"snapshot":{"exists":true,"id":"19hxT6XALz8ds00eORms","ref":{"_type":"DocumentReference","path":"apps/community/categories/19hxT6XALz8ds00eORms"}}},{"data":{"createdAt":{"_type":"Date","value":"Thu Jul 07 2022 16:36:49 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"research","sectionConfig":{"events":{"description":"Our HealthTree Research events help you learn about the latest research and studies related to your cancer, including interviews with medical specialists.","metaDescription":"Research Events to help you learn about the latest research and studies related to your cancer, including interviews with medical specialists.","metaTitle":"(disease) Research Events - HealthTree Foundation","order":5},"news":{"description":"Our HealthTree Research articles contain findings from surveys and studies inside HealthTree’s database. These surveys and studies are conducted by researchers and specialists.","metaDescription":"These articles are findings from HealthTree Research findings from surveys and studies.","metaTitle":"HealthTree Research - HealthTree Foundation","order":5,"tileOrder":2,"type":"SMALL_TILE"},"podcasts":{"order":2,"status":"ACTIVE"}},"sections":["EVENTS","NEWS"],"slug":"research","status":"ACTIVE","title":"HealthTree Research","updatedAt":{"_type":"Date","value":"Thu Apr 25 2024 18:37:49 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/BnXIg7Ru4SK5FpscX41b"},"snapshot":{"exists":true,"id":"BnXIg7Ru4SK5FpscX41b","ref":{"_type":"DocumentReference","path":"apps/community/categories/BnXIg7Ru4SK5FpscX41b"}}},{"data":{"createdAt":{"_type":"Date","value":"Sat Dec 02 2023 00:52:31 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"conferences","sectionConfig":{"news":{"description":"Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.","metaDescription":"These articles discuss the latest coverage of medical advancements from recent academic conferences.","metaTitle":"Conferences - HealthTree Foundation","order":6,"tileOrder":3,"type":"SMALL_TILE"}},"sections":["NEWS"],"slug":"conferences","status":"ACTIVE","title":"Conferences","updatedAt":{"_type":"Date","value":"Fri Apr 12 2024 20:21:44 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/j4bWXiDzhdlhMFvaeXoc"},"snapshot":{"exists":true,"id":"j4bWXiDzhdlhMFvaeXoc","ref":{"_type":"DocumentReference","path":"apps/community/categories/j4bWXiDzhdlhMFvaeXoc"}}},{"data":{"createdAt":{"_type":"Date","value":"Thu Jul 07 2022 16:35:12 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"clinical-trials","sectionConfig":{"news":{"description":"Our Clinical Trials articles highlight top clinical trials, their results, and how patients can participate in them.","metaDescription":"These articles highlight top clinical trials, their results, and how patients can participate in them.","metaTitle":"Clinical Trials - HealthTree Foundation","order":7,"tileOrder":4,"type":"SMALL_TILE"}},"sections":["NEWS"],"slug":"clinical-trials","status":"ACTIVE","title":"Clinical Trials","updatedAt":{"_type":"Date","value":"Thu Apr 25 2024 18:37:47 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/hUncpyMvyuZCF2qvA0Cv"},"snapshot":{"exists":true,"id":"hUncpyMvyuZCF2qvA0Cv","ref":{"_type":"DocumentReference","path":"apps/community/categories/hUncpyMvyuZCF2qvA0Cv"}}},{"data":{"createdAt":{"_type":"Date","value":"Thu Jul 07 2022 16:35:26 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"healthtree","sectionConfig":{"news":{"description":"Our HealthTree Programs articles highlight the programs, events, and updates of the HealthTree Foundation.","metaDescription":"These articles highlight the programs, events, and updates of the HealthTree Foundation.","metaTitle":"HealthTree Programs - HealthTree Foundation","order":8,"tileOrder":6,"type":"SMALL_TILE"}},"sections":["NEWS"],"slug":"healthtree-programs","status":"ACTIVE","title":"HealthTree Programs","updatedAt":{"_type":"Date","value":"Thu Apr 25 2024 18:37:52 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/WSTraX4hOKp92asdiTHa"},"snapshot":{"exists":true,"id":"WSTraX4hOKp92asdiTHa","ref":{"_type":"DocumentReference","path":"apps/community/categories/WSTraX4hOKp92asdiTHa"}}},{"data":{"createdAt":{"_type":"Date","value":"Thu Jul 07 2022 16:35:51 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"healthtree-press","sectionConfig":{"news":{"description":"Read articles about HealthTree's progress in major media publications in video, online and in newspapers.","metaDescription":"These articles are about HealthTree's progress in major media publications in video, online and in newspapers.","metaTitle":"HealthTree Press - HealthTree Myeloma","order":9,"tileOrder":5,"type":"SMALL_TILE"}},"sections":["NEWS"],"slug":"healthtree-press","status":"ACTIVE","title":"HealthTree Press","updatedAt":{"_type":"Date","value":"Thu Apr 25 2024 18:37:51 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/SOL2ODcbaDI1CazQRbRS"},"snapshot":{"exists":true,"id":"SOL2ODcbaDI1CazQRbRS","ref":{"_type":"DocumentReference","path":"apps/community/categories/SOL2ODcbaDI1CazQRbRS"}}}],"articlesToDisplay":[{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/GxAhXAnh3drV4xY5Vf3A-1620"},"category":{"_type":"DocumentReference","path":"apps/community/categories/SOL2ODcbaDI1CazQRbRS"},"createdAt":{"_type":"Date","value":"Mon Sep 09 2024 20:34:07 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GMiulNhUPGrzlsCN3Fmv"},"diseases":[{"_type":"DocumentReference","path":"diseases/GMiulNhUPGrzlsCN3Fmv"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"}],"headerImageUrl":"https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FJenny%20News%20_186d8e41-b120-40f8-a73d-02ba592e9f3c.png?alt=media","htmlContent":"

Jenny Ahlstrom, CEO of HealthTree Foundation, continues to champion the foundation's mission and purpose through prominent media outlets. Most recently, she was featured on FOX News (KTVU, San Francisco), to kick off Blood Cancer Awareness Month.

\n\n

Watch the segment below as Jenny discusses how blood cancer patients and their families can actively contribute to groundbreaking research in simple, impactful ways, helping accelerate the search for cancer cures.

\n\n

$\"\"$

\n\n

!AD!

\n\n

About HealthTree Foundation

\n\n

HealthTree is a global nonprofit organization uniting patients and researchers through cutting-edge technology to work together on curing diseases. HealthTree provides lifetime personalized support and education, meaningful patient-to-patient connections, and a powerful patient data portal transforming patients and caregivers into active contributors in driving lifesaving breakthroughs.

\n\n

!AD!!AD!

\n","language":"EN","metaDescription":"HealthTree Foundation’s innovative research and patient-centered approach was recently featured on Fox News.","metaTitle":"HealthTree Featured on FOX News","publishedAt":{"_type":"Date","value":"Mon Sep 09 2024 04:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"HealthTree Fox News Article, HealthTree Press Release, HealthTree Foundation News","slug":"healthtree-foundation-fox-news-feature","status":"ACTIVE","title":"HealthTree Foundation Featured on Fox News","updatedAt":{"_type":"Date","value":"Mon Sep 09 2024 21:28:23 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/sWorZoogPIDwlwLLdeBN"},"snapshot":{"exists":true,"id":"sWorZoogPIDwlwLLdeBN","ref":{"_type":"DocumentReference","path":"apps/community/articles/sWorZoogPIDwlwLLdeBN"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/GxAhXAnh3drV4xY5Vf3A-1620"},"categories":[],"category":{"_type":"DocumentReference","path":"apps/community/categories/SOL2ODcbaDI1CazQRbRS"},"createdAt":{"_type":"Date","value":"Tue Jul 16 2024 15:18:56 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GMiulNhUPGrzlsCN3Fmv"}],"headerImageUrl":"https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FJenny%20ABC%20news_b7be685e-2885-48ca-9cac-cd14b99a11f5.png?alt=media","htmlContent":"

We’re excited to share some incredible news with you today. Our founder, Jenny Ahlstrom, and HealthTree Coach, Tony Newberne, were featured on ABC News with Mara Bush!

\n\n

In this inspiring segment, Jenny and Tony explain how HealthTree’s groundbreaking technology and patients' invaluable contributions power the search for blood cancer cures.

\n\n

We invite you to watch in the video below.

\n\n

About HealthTree Foundation

\n\n

\n","isBmh":true,"language":"EN","metaDescription":"HealthTree Foundation’s innovative research and patient-centered approach was recently featured on ABC News.","metaTitle":"HealthTree Featured on ABC News","publishedAt":{"_type":"Date","value":"Tue Jul 16 2024 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"HealthTree ABC News Article, HealthTree Press Release, HealthTree Foundation News","slug":"healthtree-foundation-abc-news-feature","status":"ACTIVE","title":"HealthTree Foundation Featured on ABC News","updatedAt":{"_type":"Date","value":"Thu Aug 08 2024 15:27:03 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/ClKhx3YQ7vbZvnmmsaz7"},"snapshot":{"exists":true,"id":"ClKhx3YQ7vbZvnmmsaz7","ref":{"_type":"DocumentReference","path":"apps/community/articles/ClKhx3YQ7vbZvnmmsaz7"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/GxAhXAnh3drV4xY5Vf3A-1620"},"categories":[{"_type":"DocumentReference","path":"apps/community/articleCategories/38"}],"category":{"_type":"DocumentReference","path":"apps/community/categories/SOL2ODcbaDI1CazQRbRS"},"createdAt":{"_type":"Date","value":"Wed Feb 28 2024 23:09:20 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GMiulNhUPGrzlsCN3Fmv"}],"headerImageUrl":"https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FResearch%20Hub_24d132bd-95b3-43c8-9ca8-4df83cf1b663.png?alt=media","htmlContent":"

We're excited to announce the exciting and anticipated launch of HealthTree Foundation's HealthTree Research Hub. This portal uses cutting-edge technology to unite patients and researchers in order to accelerate cures and facilitate real-world data for researchers around the world. The Research Hub is being launched in multiple myeloma today.

\n\n

HealthTree Foundation Founder, Jenny Ahlstrom, shares more about the exciting launch in the video below.

\n\n

Check out the press release here or continue reading to learn more about this exciting advancement in myeloma research and technology.

\n\n

HealthTree Research Hub is an online research portal that facilitates real-world data (RWD) research. HealthTree Research Hub provides researchers access to over 14,000 myeloma patients who contribute anonymized data to the HealthTree Cure Hub patient portal.

\n\n

This data includes electronically imported EHR data (labs, genetics, prior lines of therapy, outcome data, etc) as well as patient-contributed data such as patient-reported outcomes (PRO) and demographics.

\n\n

Patients can also respond to investigator surveys or studies inside of HealthTree Cure Hub. The data is validated by a team of HealthTree medical professionals (also known as disease navigators.)

\n\n

The tool builds a living, ongoing, and interactive relationship between patients and researchers, opening revolutionary approaches to new research that save time, money, and lives.

\n\n

\n
“HealthTree Research Hub is the only tool that enables access to larger, more comprehensive and constantly updated data sets,” said Jenny Ahlstrom, HealthTree CEO and Founder. ”Traditional RWD challenges of incomplete or inaccurate data, missing patient reported outcomes or lost-to-follow up issues are overcome because of the ongoing, interactive relationship HealthTree maintains with patients and its validation process.”
\n

\n\n

Rafael Fonseca, MD and Chief Innovation Officer, Mayo Clinic, shares:

\n\n

\n
“HealthTree Research Hub opens new doors to the research community by providing access to complete, validated RWD [real-world data] from both directly connected EHRs and patients themselves...[t]hank you HealthTree for building the tools we need to invite thousands of patients to contribute to research outside of clinical trials in order to drive faster cures.”
\n

\n\n

In HealthTree Research Hub, myeloma investigators can perform data mining, chart reviews, synthetic control arm comparisons, or surveys and studies. Researchers are provided a login/password and R-studio research tools to analyze subsets of anonymized data based on project needs.

\n\n

\n
“HealthTree had the financial resources, a willing virtual patient base and the research tools available so we could survey patients and gather their responses via an IRB approved protocol,” said Craig Hofmeister, MD, Emory University. “Their team worked collaboratively with us to create the survey, distribute it to the patients, analyze the results and craft the future publication. It's been a great experience for our team."
\n

\n\n

HealthTree Research Hub will facilitate over 100 research projects in the next 20 months for myeloma researchers. A call for multiple myeloma research proposals begins March 1, 2024. Any researcher who joins the HealthTree Research Network will be provided free access to the data. If you are a licensed physician treating multiple myeloma, you can start your application today here: Submit Myeloma Research Proposal

\n\n

HealthTree Research Hub will be performing beta research projects in lymphoma, leukemia, and MPNs in 2024.

\n\n

If you are looking to participate in myeloma research as or on behalf of a myeloma patient, we invite you to do the following:

\n\n

1. Connect your medical records to our database in HealthTree Cure Hub today. It's quick and easy, and you can share your records with confidence that your personal information will be kept private. All information shared with researchers is anonymized. We value your privacy and your security.

\n\n

2. Stay tuned to our News Site during March, Myeloma Awareness Month. Our goal this month is to help you be aware of research opportunities for you and your doctor. We will publish articles each week with action steps on how to participate and allow others to do the same. Share these with those in your myeloma circles.

\n\n

3. Participate in surveys and studies within HealthTree Cure Hub. This can take 3-5 minutes of your time and influence the way that healthcare providers are treating myeloma patients. Join Cure Hub and start participating today.

\n","language":"EN","metaDescription":"HealthTree Foundation is using innovative technology to provide ongoing myeloma real-world data for researchers in the new HealthTree Research Hub Portal.","metaTitle":"HealthTree Research Hub Launched in Myeloma","migratedReason":"global-community","migratedReason2":"fix global-community categories","oldCategory":{"_type":"DocumentReference","path":"apps/community/categories/SOL2ODcbaDI1CazQRbRS"},"publishedAt":{"_type":"Date","value":"Fri Mar 01 2024 07:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"healthtree foundation, healthtree for myeloma, healthtree for multiple myeloma, healthtree research, healthtree cure hub, healthtree research hub, myeloma research, myeloma research hub,","slug":"healthtree-research-hub-announced","status":"ACTIVE","title":"HealthTree Foundation Announces Launch of HealthTree Research Hub in Multiple Myeloma","updatedAt":{"_type":"Date","value":"Wed Jul 03 2024 16:21:22 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/WpOLAW7lUHFXH4ICI2K3"},"snapshot":{"exists":true,"id":"WpOLAW7lUHFXH4ICI2K3","ref":{"_type":"DocumentReference","path":"apps/community/articles/WpOLAW7lUHFXH4ICI2K3"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/s6tTUs3C9i1oJP7fJj9i"},"categories":[{"_type":"DocumentReference","path":"apps/community/articleCategories/SiyYj6yjD0FJpxsRlpH2"}],"category":{"_type":"DocumentReference","path":"apps/community/categories/SOL2ODcbaDI1CazQRbRS"},"createdAt":{"_type":"Date","value":"Thu Sep 28 2023 17:05:50 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/cll"}],"headerImageUrl":"https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2Fhealthtree2.0updated_8cfd036b-4573-4e49-985d-be175374d2d1.png?alt=media","htmlContent":"

Blood Cancer Awareness Month may be drawing to a close, but for HealthTree, we are taking a substantial leap forward. HealthTree is expanding its blood cancer reach from supporting multiple myeloma and chronic lymphocytic leukemia (CLL) to now all blood cancers.

\n\n

HealthTree is poised to revolutionize the landscape of blood cancer support with the launch of HealthTree 2.0 on October, 23rd 2023. Our groundbreaking platform will now support 35 types of blood cancers, including all types of leukemia, lymphoma, and myeloproliferative neoplasms. This new era reaffirms our dedication to providing unmatched support, knowledge, and resources to a wider community of blood cancer patients and their care partners.

\n\n

An Overview of HealthTree Foundation

\n\n

In addition to offering unparalleled educational resources aimed at helping patients become active members in their care, HealthTree is known for its first-of-its-kind data portal called CureHub, where its primary mission is to accelerate a cure for blood cancers. CureHub allows patients to securely share their validated diagnosis, lab values, disease genetics, patient-reported outcomes, family history, and more in a single place for researchers and scientists to analyze with the goal of accelerating research toward a cure.

\n\n

For the past decade, our accomplishments in the fields of myeloma and CLL have been a source of inspiration. From helping patients access clinical trials to fostering collaboration between patients, caregivers, and medical professionals, we have strived to be a trusted ally in the battle against blood cancer. But we recognize that blood cancers come in a wide variety of forms, and our vision for a world free of blood cancers extends to every patient and every type of blood cancer.

\n\n

Now, with the introduction of HealthTree 2.0, we embark on a new chapter, extending our mission to all forms of blood cancers. To view all the blood cancers that HealthTree now supports, visit www.healthtree.org. Enter your or your loved one's blood cancer name in the search bar to visit the disease-specific website and access the programs and resources that are personalized to your type of cancer.

\n\n

HealthTree’s 3 Pillars: A Glimpse into the Future

\n\n

All of our core programs and resources will be tailored thoughtfully for each of our 35 blood cancer divisions. Everything we do will lie within HealthTree 2.0’s three foundational pillars:

\n\n

Lifetime Personalized Support and Education: This pillar empowers individuals with the knowledge and tools necessary to make informed decisions regarding their treatment and care.
Meaningful Patient-to-Patient Connections: By fostering personal connections between patients, individuals will find comfort in knowing they are not alone and become able to support one another, share key resources and feel empowered to help find a cure.
A Powerful Patient Data Portal called HealthTree Cure Hub: This powerful portal revolutionizes the sharing and utilization of patient data in the fight against blood cancer.

\n\n

You can view a detailed breakdown of the programs and resources each of our 35 blood cancer divisions will have within our three pillars in the picture below. All of our new blood cancer websites will start with news, a specialist directory, HealthTree Journal, patient navigator support, HealthTree Connect, HealthTree Moves and every section of Cure Hub except treatment options. Our dedicated and passionate 60-person team will be working hard to roll out the remaining programs and resources throughout 2024!

\n\n

$\"\"$

\n\n

Be Part of the Revolution: Attend the HealthTree 2.0 Launch Event!

\n\n

Don't miss our virtual HealthTree 2.0 Launch Event on October 23, 2023! Join us in exploring the future of blood cancer care and discover how you can play a pivotal role in accelerating a cure for CLL and all types of blood cancer.

\n\n

Register for our virtual launch today and extend the invitation to everyone you know! While you may have been affected by CLL, it's likely you also know someone else with a different type of blood cancer. By uniting together, we can reshape the landscape of blood cancer care and ensure everyone affected by blood cancer achieves a cure.

\n\n

Links to HealthTree’s Blood Cancer Websites:

\n\n

Leukemia

\n\n

HealthTree for Acute Lymphoblastic Leukemia

\n\n

HealthTree for Acute Myeloid Leukemia

\n\n

HealthTree for B-Cell Prolymphocytic Leukemia

\n\n

HealthTree for Blastic Plasmacytoid Dendritic Cell Neoplasm

\n\n

HealthTree for Chronic Lymphocytic Leukemia

\n\n

HealthTree for Chronic Myeloid Leukemia

\n\n

HealthTree for Chronic Myelomonocytic Leukemia

\n\n

HealthTree for Hairy Cell Leukemia

\n\n

HealthTree for Large Granular Lymphocytic Leukemia

\n\n

HealthTree for T-Cell Prolymphocytic Leukemia

\n\n

Lymphoma

\n\n

HealthTree for Angioimmunoblastic T-Cell Lymphoma

\n\n

HealthTree for Anaplastic Large Cell Lymphoma

\n\n

HealthTree for Burkitt Lymphoma

\n\n

HealthTree for Small-Cell Lymphocytic Lymphoma

\n\n

HealthTree for Cutaneous T-Cell Lymphoma

\n\n

HealthTree for Diffuse Large B-Cell Lymphoma

\n\n

HealthTree for Enteropathy-Associated Intestinal T-Cell Lymphoma

\n\n

HealthTree for Follicular Lymphoma

\n\n

HealthTree for Extranodal Natural Killer Lymphoma

\n\n

HealthTree for Hepatosplenic T-Cell Lymphoma

\n\n

HealthTree for Hodgkin Lymphoma

\n\n

HealthTree for Lymphoblastic Lymphoma

\n\n

HealthTree for Mantle Cell Lymphoma

\n\n

HealthTree for Marginal Zone Lymphoma

\n\n

HealthTree for Mucosa-Associated Lymphoid Tissue Lymphoma

\n\n

HealthTree for Peripheral T-Cell Lymphoma

\n\n

HealthTree for Primary Mediastinal B-Cell Lymphoma

\n\n

HealthTree for Waldenstrom's Macroglobulinemia

\n\n

Myeloproliferative Neoplasms (MPNs)

\n\n

HealthTree for Myelodysplastic Syndromes

\n\n

HealthTree for Myelofibrosis

\n\n

HealthTree for Essential Thrombocythemia

\n\n

HealthTree for Polycythemia Vera

\n\n

HealthTree for Mastocytosis

\n\n

HealthTree for Hypereosinophilic Syndrome

\n\n

Multiple Myeloma

\n\n

HealthTree for Multiple Myeloma

\n","language":"EN","metaDescription":"Blood Cancer Awareness Month may be drawing to a close, but for HealthTree, the journey of blood cancer awareness and advocacy continues forward.","metaTitle":"HealthTree 2.0: A New Era in Blood Cancer Support","migratedReason":"global-community","migratedReason2":"fix global-community categories","oldAuthor":{"_type":"DocumentReference","path":"apps/community/authors/GPyS5JKmulMlj7PDBGuk"},"oldCategory":{"_type":"DocumentReference","path":"apps/community/categories/OPxhXslDftmUeXIYkh75"},"publishedAt":{"_type":"Date","value":"Fri Sep 29 2023 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"chronic lymphocytic leukemia, cll, cll cancer, cll leukemia, lymphocytic leukemia, chronic leukemia, lymphocytic, cll sll, cll disease, b cll, chronic lymphocytic leukemia, cll, cll support, blood cancer, blood cancer advocacy, blood cancer support, healthtree foundation, healthtree 2.0, healthtree for cll","slug":"healthtree-2-0-a-new-era-cll","status":"ACTIVE","title":"HealthTree 2.0: Expanding Our Reach to Support All Blood Cancers","updatedAt":{"_type":"Date","value":"Tue Apr 02 2024 12:16:15 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/ahLiRkQPveqDNpq64JwI"},"snapshot":{"exists":true,"id":"ahLiRkQPveqDNpq64JwI","ref":{"_type":"DocumentReference","path":"apps/community/articles/ahLiRkQPveqDNpq64JwI"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/GxAhXAnh3drV4xY5Vf3A-1620"},"categories":[{"_type":"DocumentReference","path":"apps/community/articleCategories/SiyYj6yjD0FJpxsRlpH2"}],"category":{"_type":"DocumentReference","path":"apps/community/categories/SOL2ODcbaDI1CazQRbRS"},"createdAt":{"_type":"Date","value":"Fri Sep 08 2023 01:41:14 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/cll"}],"headerImageUrl":"https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FPillar%20three%20edited_d3358199-7961-4ac2-ba27-3a6d8a643139.jpg?alt=media","htmlContent":"

In preparation for our exciting October 23rd HealthTree 2.0 Launch, we've recently highlighted both Pillar One and Pillar Two of the new and improved HealthTree 2.0 model on our website.

\n\n

These pillars, targeted to help educate and connect the CLL community, are essential as they build empowered, trusting relationships with communities that are then ready and willing to contribute toward a cure.

\n\n

Today, we focus on the third and final pillar that makes up the HealthTree 2.0 Model: a Powerful Patient Data Portal.

\n\n

Our data patient portal, HealthTree Cure Hub, is designed to help patients and caregivers give back by connecting their medical data in a private, secure way. Researchers can analyze this anonymous data to come up with real-world solutions to complex CLL issues.

\n\n

Patients are also invited to participate in researcher-led studies and surveys to further key CLL research.

\n\n

The Purpose of a Powerful Patient Data Portal within HealthTree’s Model

\n\n

HealthTree Cure Hub, though technically "one program" within the foundation, consists of many easy-to-use, everyday tools that help you navigate your CLL and, at the same time, accelerate a CLL cure.

\n\n

When you're first diagnosed, it's hard to trust the multitude of information that's coming at you. That's where Pillar One, as mentioned before, comes into play because it helps organize, personalize, and simplify your CLL education. Pillar Two allows educated patients to become connected with one another and their communities. Pillar Three, HealthTree Cure Hub, gives patients (and caregivers) a chance to give back.

\n\n

How does HealthTree Cure Hub get us to a CLL cure? It facilitates research! Patients and CLL investigators have pressing health questions and we created Cure Hub to answer those critical medical questions today. Through HealthTree Cure Hub, we will run queries (studies and surveys) led by top CLL investigators.

\n\n

Patients will have the chance to participate in these necessary studies and surveys, giving the researchers the ability to analyze the anonymized data to find the answers they are looking for.

\n\n

Because we will have the ability to access so many patients, we are able to cut recruiting time and money in half. Researchers have access to anonymized, validated data instead of spending a fortune in time and money trying to collect a patient data subset on their own.

\n\n

Doctors (oncologists and specialists alike) often complain they don’t have access to the patient’s complete health story, but Cure Hub allows doctors and patients to be on the same page about the patient’s health profile. Researchers believe a cure will come after understanding the full picture of the patient’s health history compared to others like them.

\n\n

HealthTree Programs within HealthTree Cure Hub

\n\n

HealthTree Cure Hub consists of many patient-friendly tools that help you manage your chronic lymphocytic leukemia.

\n\n

Track Your CLL Labs

\n\n

In Cure Hub, you can track all your CLL labs in a single place, so you don’t have to create or maintain a separate spreadsheet.

\n\n

Clinical Trial Finder (Coming Soon with Personalization!)

\n\n

HealthTree Cure Hub can currently search through hundreds of open CLL clinical trials. Enhanced personalization is coming shortly to help you narrow the list down to only those clinical trials you are eligible to join.

\n\n

CLL Twin Machine

\n\n

As our CLL Cure Hub database grows, you will be able to find and connect with patients who have similar experiences or genetics using our twin machine technology.

\n\n

Side Effect Solutions

\n\n

You can also use our Side Effect feature where you can see hundreds of side effects and thousands of crowd-sourced solutions provided by patients. Learn from your peers to see what worked and what didn’t to manage the most common CLL side effects.

\n\n

Surveys and Studies (coming soon)

\n\n

Soon you will be able to contribute your answers to critical questions CLL patients and researchers are asking today to help us drive faster to a CLL cure. In this section, you will soon find surveys and studies led by top CLL experts that you can participate in.

\n\n

To participate in these amazing features and get the full advantage from them, make sure that you connect your medical records. This is a secure and private connection, and your personal data will never be sold/shared without being completely anonymized.

\n\n

If you need help accessing any of these features, or connecting your medical records, or have questions in general about our research portal, contact our Patient Experience Team.

\n\n

Invitation to Participate in the Future of Chronic Lymphocytic Leukemia

\n\n

At HealthTree we believe no one should have to face CLL alone. We encourage you to sign up for a HealthTree Cure Hub account to investigate all the tools and features provided to help you make the best CLL decisions possible.

\n\n

You can learn about the new and improved HealthTree model, our goals, and how you can be involved in our upcoming HealthTree 2.0 event. Invite your friends & family and join us on October 23, 2023, to hear how you can get your best care and contribute to accelerating a CLL cure.

\n\n

\n","language":"EN","metaDescription":"The HealthTree Foundation is excited to present its new and improved model to help patients and caregivers find support and accelerate a cure.","metaTitle":"A Powerful Patient Data Portal","migratedReason":"global-community","migratedReason2":"fix global-community categories","oldAuthor":{"_type":"DocumentReference","path":"apps/community/authors/dgpNLrVI0YJktfzGS0Ua"},"oldCategory":{"_type":"DocumentReference","path":"apps/community/categories/OPxhXslDftmUeXIYkh75"},"publishedAt":{"_type":"Date","value":"Sun Sep 10 2023 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"chronic lymphocytic leukemia, cll, cll cancer, cll leukemia, lymphocytic leukemia, chronic leukemia, lymphocytic, cll sll, cll disease, b cll, cll, chronic lymphocytic leukemia, cll support, chronic lymphocytic leukemia support, healthtree foundation, healthtree for cll, cll research, cll studies, cll clinical trials, cll surveys","slug":"healthtree-2-pillar-three-cll","status":"ACTIVE","title":"HealthTree 2.0 Pillar Three: A Powerful Patient Data Portal ","updatedAt":{"_type":"Date","value":"Tue Apr 02 2024 12:09:15 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/7Zceiqk8LFNGML2MfXIB"},"snapshot":{"exists":true,"id":"7Zceiqk8LFNGML2MfXIB","ref":{"_type":"DocumentReference","path":"apps/community/articles/7Zceiqk8LFNGML2MfXIB"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/GxAhXAnh3drV4xY5Vf3A-11"},"categories":[{"_type":"DocumentReference","path":"apps/community/articleCategories/SiyYj6yjD0FJpxsRlpH2"}],"category":{"_type":"DocumentReference","path":"apps/community/categories/SOL2ODcbaDI1CazQRbRS"},"createdAt":{"_type":"Date","value":"Wed Sep 06 2023 21:57:58 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/cll"}],"headerImageUrl":"https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2Fpillar%20two%20edited_b8b74eae-0239-4c14-afb1-9f1d502c6607.jpg?alt=media","htmlContent":"

As I look back on the past eight years supporting my husband since his diagnosis with blood cancer I recognize the process we went through to get where we are today. At diagnosis, we were terrified and completely unaware of what we were about to face.

\n\n

As we became educated we sought out a second opinion and the best treatment options. Education and information gave us more peace and direction. We were soon eager to talk with and connect with other patients and caregivers to learn from them.

\n\n

Those connections provided comfort and personalized support. We were then ready to give back and got involved in fundraising for a cure.

\n\n

HealthTree recognizes this is a common path many blood cancer patients and caregivers travel. We have created tools and programs for each phase of the CLL journey.

\n\n

The Purpose of Meaningful Patient-to-Patient Connections within HealthTree’s Model

\n\n

At HealthTree, we recognize the power of personal connection and have developed a suite of programs that offer meaningful patient-to-patient connections.

\n\n

When CLL patients and caregivers connect with others they find comfort in knowing they are not alone, are able to support one another, and share key resources. They enlarge their circle of influence and feel part of a community.

\n\n

As patients are educated and connected with others they feel empowered and want to be involved in moving forward and helping find a CURE.

\n\n

HealthTree Programs within Pillar Two: Meaningful Patient-to-Patient Connections

\n\n

There are a variety of HealthTree programs and tools that provide meaningful connections.

\n\n

HealthTree MOVES

\n\n

The HealthTree MOVES app brings patients and caregivers together to participate in fitness challenges held throughout the year. Participants can find support, encouragement, and community as they share their progress in becoming more fit and healthy.

\n\n

HealthTree MOVES is run by blood cancer patient Michelle Peterson, who knows firsthand the impact health and fitness make on life. She makes the effort to personally get to know participants and encourage and motivate them in their personal fitness journey.

\n\n

HealthTree Connect

\n\n

HealthTree created its own social media tool to allow CLL patients to find focused information.

\n\n

Individuals can post questions, share resources and personal experiences with others in the CLL community. This tool is thoughtfully run and moderated by multiple team members with moderation by blood cancer patient Michelle Peterson and direction from blood cancer caregiver Rozalynn Hite.

\n\n

HealthTree Coach

\n\n

The HealthTree Coach program provides personalized one-on-one support from CLL patients and caregivers to others. Coaches share their personal CLL experience and valuable resources to help others.

\n\n

Coaches find meaning in sharing their experiences, and Coachees feel supported and empowered by knowing they are not alone. The Coach program is led by blood cancer caregiver Rozalynn Hite.

\n\n

Invitation to Participate in the Future of CLL

\n\n

At HealthTree we believe no one should have to face CLL alone. We encourage you to utilize the programs within Pillar Two to find connection, personalized support, and community. The next step is to become a part of the CLL cure by participating in HealthTree Cure Hub's CLL research.

\n\n

\n","language":"EN","metaDescription":"The HealthTree Foundation is excited to present its new and improved model to help patients and caregivers find support and accelerate a cure.","metaTitle":"HealthTree Model Pillar 2: Meaningful Connections","migratedReason":"global-community","migratedReason2":"fix global-community categories","oldAuthor":{"_type":"DocumentReference","path":"apps/community/authors/W3Xm7yECF0KCsIvixqql"},"oldCategory":{"_type":"DocumentReference","path":"apps/community/categories/OPxhXslDftmUeXIYkh75"},"publishedAt":{"_type":"Date","value":"Fri Sep 08 2023 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"chronic lymphocytic leukemia, cll, cll cancer, cll leukemia, lymphocytic leukemia, chronic leukemia, lymphocytic, cll sll, cll disease, b cll, cll, chronic lymphocytic leukemia, cll support, chronic lymphocytic leukemia support, cll education, blood cancer, blood cancer awareness, healthtree, healthtree foundation, healthtree for cll, cancer innovation","slug":"healthtree-2-pillar-2-cll","status":"ACTIVE","title":"HealthTree 2.0 Pillar Two: Meaningful Patient to Patient Connections","updatedAt":{"_type":"Date","value":"Tue Apr 02 2024 12:20:13 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/wvtjpz2LHUQAtQUAIvqR"},"snapshot":{"exists":true,"id":"wvtjpz2LHUQAtQUAIvqR","ref":{"_type":"DocumentReference","path":"apps/community/articles/wvtjpz2LHUQAtQUAIvqR"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/GxAhXAnh3drV4xY5Vf3A-1620"},"categories":[{"_type":"DocumentReference","path":"apps/community/articleCategories/SiyYj6yjD0FJpxsRlpH2"}],"category":{"_type":"DocumentReference","path":"apps/community/categories/SOL2ODcbaDI1CazQRbRS"},"createdAt":{"_type":"Date","value":"Wed Sep 06 2023 19:59:36 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/cll"}],"headerImageUrl":"https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2Fpillar%20one%20edited%20_8ff2d702-0e65-4520-9dbf-e29e8308b199.jpg?alt=media","htmlContent":"

In lieu of the HealthTree 2.0 Launch Event announced yesterday morning, we wanted to share with you some of the exciting improvements that you will begin to see within our HealthTree Foundation for Chronic Lymphocytic Leukemia.

\n\n

Our Foundation has grown significantly within the last three years, with many developed programs improving and even more successful programs being developed.

\n\n

The HealthTree 2.0 Model will consist of 3 core pillars into which all of our programs can be organized.

\n\n

We believe that by encouraging our community to interact with our programs through these three pillars, patients and caregivers alike will remain empowered, educated individuals who make important connections with their CLL community and participate in key research that leads to a CLL cure.

\n\n

Today, we will highlight the first pillar of the HealthTree 2.0 Model: Personalized, Lifetime Support and Education.

\n\n

The Purpose of Personalized, Lifetime Support and Education within the HealthTree Model

\n\n

Several of our programs at HealthTree are geared towards personalized, lifetime support and education. We believe that by empowering CLL patients and their loved ones to learn all that they can about the disease, find specialists who stay on top of the latest and greatest, and become active partners in their care will both live longer and live a higher quality of life.

\n\n

In fact, we have seen that through the many patients and caregivers that we have helped along the way.

\n\n

When these empowered members of our community feel supported and have a trusted team to which they can ask their questions, there’s no limit to how involved and active they can be in their own care.

\n\n

Blood cancer patient Jean Becker shares,

\n\n

\n
“My first observation when engaging with HealthTree, was that it is patient-centered/focused, so I could access and understand information.
\n\n
The breadth and depth of resources as well as timeliness (current), is so helpful and supportive. No matter what my questions are, from testing to treatments, to side effects, I can always find answers, information, or a direction.
\n\n
And if they aren't there, I can ask, and get answers.
\n\n
The community is so supportive. The range of experts and access to them, and their knowledge through the courses, or regular webinars, chapters, etc. has been crucial to my journey, as I feel prepared to advocate for myself and others with good information and data.”
\n

\n\n

HealthTree Programs within Pillar One: Personalized Lifetime Support and Education

\n\n

HealthTree Podcast for CLL

\n\n

Our podcast program, in which we interview CLL specialists about their open clinical trials and other hot topics in CLL, was the very first program within our foundation.

\n\n

Jenny, HealthTree's Founder and CEO, as a patient herself, was having a hard time finding a clinical trial that she qualified for in her area. She decided to take things into her own hands and start interviewing doctors to make it easier for her and others like her to understand clinical trials and know how to sign up for one.

\n\n

New podcast episodes continue to be released, with many patients claiming this as their favorite educational program.

\n\n

HealthTree News for CLL

\n\n

Part of providing personalized lifetime education includes publishing up-to-date, easy-to-understand information about the latest and greatest in CLL. On our news site, you can read articles about newly approved CLL medications, results of clinical trials, CLL patient stories, and much more.

\n\n

\n
“The HealthTree Foundation programs have helped keep me up to date on the ever-changing landscape of treatments,” says blood cancer patient Angela Perez, “I can always count on HealthTree to have the latest news on the newest treatments and clinical trials available.”
\n

\n\n

HealthTree Webinars for CLL

\n\n

Our HealthTree webinar program launched in October 2021. The program began in the midst of a global pandemic when many immunocompromised patients and their families had to remain at home.

\n\n

Different groups were created and called Chapters, in which people could search for webinars based on their interests, the current status of their disease, or their demographic. In CLL, we started broadly with an Adult CLL chapter and a CLL Caregiver chapter. In the future, we plan to open new chapters like various CLL treatment-specific chapters.

\n\n

We are dedicated to providing personalized education through these webinars and inviting top experts to educate the community on the most crucial CLL topics.

\n\n

HealthTree University

\n\n

Perhaps our most popular program, HealthTree University has drastically changed the way that the CLL community can educate themselves about complex CLL topics.

\n\n

The HealthTree University team interviews CLL specialists at conferences and other events to get their expert opinions on questions that matter to CLL patients. The original curriculum was developed by Cindy Chmielewski, a former teacher and blood cancer patient (and also Twitter queen @myelomateacher).

\n\n

HealthTree Patient Experience Team

\n\n

In addition to education, we strive to provide support to each of our community members.

\n\n

Our Patient Experience team, led by Ana Sahagun, consists of a patient navigation and medical navigation team.

\n\n

The Patient Navigation team can help you find CLL resources, answer questions about our website, and troubleshoot any issues you may have.

\n\n

Our Medical Navigation team can help you answer questions that you have about CLL (although they cannot give medical advice), aid you in understanding what your personalized lab values mean, and provide insight on general CLL medication questions that you may have.

\n\n

You can contact them by emailing support@healthtree.org, or calling/texting +1 800 709 1113.

\n\n

HealthTree for CLL Website

\n\n

The rest of our website includes many resources such as:

\n\n

You can explore our website or contact our team if you are looking for specific resources.

\n\n

Invitation to Participate in the Future of CLL

\n\n

At HealthTree, we believe no one should have to face CLL alone.

\n\n

We encourage you to utilize the programs within Pillar One to educate yourself, your loved ones, and find personalized, lifetime support as you go along your CLL journey. The next step is to become a part of the CLL cure by participating in HealthTree Cure Hub's CLL research.

\n\n

\n","language":"EN","metaDescription":"The HealthTree Foundation is excited to present its new and improved model to help patients and caregivers find support and accelerate a cure.","metaTitle":"HealthTree Model Pillar One: Support and Education","migratedReason":"global-community","migratedReason2":"fix global-community categories","oldAuthor":{"_type":"DocumentReference","path":"apps/community/authors/dgpNLrVI0YJktfzGS0Ua"},"oldCategory":{"_type":"DocumentReference","path":"apps/community/categories/OPxhXslDftmUeXIYkh75"},"publishedAt":{"_type":"Date","value":"Thu Sep 07 2023 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"chronic lymphocytic leukemia, cll, cll cancer, cll leukemia, lymphocytic leukemia, chronic leukemia, lymphocytic, cll sll, cll disease, b cll, healthtree foundation, healthtree for cll, chronic lymphocytic leukemia, cll support, cll education, blood cancer, blood cancer awareness, blood cancer education, cure cll, cure leukemia","slug":"healthtree-2-pillar-one-cll","status":"ACTIVE","title":"HealthTree 2.0 Pillar One: Personalized, Lifetime Support and Education","updatedAt":{"_type":"Date","value":"Tue Apr 02 2024 12:12:29 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/GuRuLae6OlDN2sUietCb"},"snapshot":{"exists":true,"id":"GuRuLae6OlDN2sUietCb","ref":{"_type":"DocumentReference","path":"apps/community/articles/GuRuLae6OlDN2sUietCb"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/GxAhXAnh3drV4xY5Vf3A-3"},"categories":[{"_type":"DocumentReference","path":"apps/community/articleCategories/SiyYj6yjD0FJpxsRlpH2"}],"category":{"_type":"DocumentReference","path":"apps/community/categories/SOL2ODcbaDI1CazQRbRS"},"createdAt":{"_type":"Date","value":"Tue Sep 05 2023 20:09:01 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/cll"}],"headerImageUrl":"https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2Fhealthtree2.0updated_8cfd036b-4573-4e49-985d-be175374d2d1.png?alt=media","htmlContent":"

Today, the HealthTree Foundation is thrilled to announce its highly anticipated HealthTree 2.0 Launch on October 23, 2023.

\n\n

Using a successful, comprehensive, and technically innovative model proven in multiple myeloma, HealthTree 2.0 will announce further growth in multiple myeloma as well as the expansion of HealthTree Foundation into all blood cancers.
\n
\nThe HealthTree 2.0 “Using Technology and Revolutionary Approaches to Cure Cancer” event will be hosted live at the Montage Hotel in Deer Valley, Utah, and will be livestreamed online.

\n\n

Keynote speakers will include Fred Appelbaum, MD, Executive Vice President at Fred Hutch Cancer Center and author of Living Medicine, Rafael Fonseca, MD, Chief Innovation Officer at Mayo Clinic; and Jeffrey Wolf, MD, Myeloma Director at UCSF.

\n\n

Marking the commencement of its second decade of groundbreaking innovation and unique creation of technology tools, HealthTree 2.0 promises to redefine the landscape of support for blood cancer patients and their families using 14 in-house developed software “cure tools” that fall into three pillars.

\n\n

Personalized, lifetime support and education
Meaningful patient-to-patient connections
A powerful patient data portal

\n\n

The data portal, called HealthTree Cure Hub, uniquely transforms patients into active contributors toward a cancer cure by facilitating faster research using longitudinal real-world evidence (RWE) and enabling ongoing patient participation in surveys and studies.

\n\n

After a successful first decade providing multiple myeloma and acute myeloid leukemia patients with the most tech-enabled, comprehensive services and tools provided by any patient advocacy organization, HealthTree 2.0 ushers in a new era of patient empowerment and research potential to even more patients and caregivers in need.

\n\n

\n
“HealthTree 2.0 is not just an event, it’s a pivotal moment for blood cancer patients dealing with a challenging cancer. Until now, most of them have navigated their cancer journey using incomplete support programs, siloed systems, and a lack of data,” said Jenny Ahlstrom, CEO of HealthTree Foundation. “This event signifies the dawn of a new era where patients, caregivers, and family members are not only educated, supported, and connected, but are given the tools to meaningfully contribute their experiences to academic research.”
\n

\n\n

We invite patients and caregivers to register for the event, create their own virtual satellite events to join the October 23rd livestream, and learn more about this exciting new era.

\n\n

In preparation for the event, we invite you to purchase a copy of Living Medicine, the story of the beginnings of stem cell transplant as an example of the impact innovation can have in patients’ lives.

\n\n

For more information on the HealthTree Foundation and the HealthTree 2.0 Launch, read the press release here.

\n","language":"EN","metaDescription":"HealthTree Announces the Launch of HealthTree 2.0, our second decade of expansion now focused on accelerating cures for all people with blood cancer.","metaTitle":"HealthTree Announces Launch of HealthTree 2.0","migratedReason":"global-community","migratedReason2":"fix global-community categories","oldAuthor":{"_type":"DocumentReference","path":"apps/community/authors/1tQvtn2OPLrh6zPvAUQH"},"oldCategory":{"_type":"DocumentReference","path":"apps/community/categories/OPxhXslDftmUeXIYkh75"},"publishedAt":{"_type":"Date","value":"Wed Sep 06 2023 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"Chronic lymphocytic leukemia, cll, what is new in cll, cll events, cll community, cll groups, cll support groups, blood cancer support groups, blood cancer, healthtree foundation, blood cancer event, blood cancer webinar, cancer innovation, new cll treatments","slug":"healthtree-launch-annoucement-cll","status":"ACTIVE","title":"Announcing the Launch of HealthTree 2.0 on October 23rd","updatedAt":{"_type":"Date","value":"Tue Apr 02 2024 12:16:19 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/bA5QOJ3RstpRNsv1EMVg"},"snapshot":{"exists":true,"id":"bA5QOJ3RstpRNsv1EMVg","ref":{"_type":"DocumentReference","path":"apps/community/articles/bA5QOJ3RstpRNsv1EMVg"}}}],"categoryById":{"19hxT6XALz8ds00eORms":{"description":"Our Patient Stories articles contain patient and caregiver experiences, along with their advice for others going through similar circumstances.","metaDescription":"Read patient stories to learn about other’s experiences and what advice they have for people going through similar circumstances.","metaTitle":"Patient Stories - HealthTree Foundation","slug":"patient-stories","title":"Patient Stories"},"BnXIg7Ru4SK5FpscX41b":{"description":"Our HealthTree Research articles contain findings from surveys and studies inside HealthTree’s database. These surveys and studies are conducted by researchers and specialists.","metaDescription":"These articles are findings from HealthTree Research findings from surveys and studies.","metaTitle":"HealthTree Research - HealthTree Foundation","slug":"research","title":"HealthTree Research"},"MB3xw38fuKkx0LdszsrL":{"description":"Our Core Education articles help you understand your cancer so you are equipped to find a good care team, ask appropriate questions, and become your own best advocate.","metaDescription":"Learn 101 Education to help you know more about your cancer, what tests and treatments are available to you, and more.","metaTitle":"Core Education - HealthTree Foundation","slug":"core-education","title":"Core Education"},"SOL2ODcbaDI1CazQRbRS":{"description":"Read articles about HealthTree's progress in major media publications in video, online and in newspapers.","metaDescription":"These articles are about HealthTree's progress in major media publications in video, online and in newspapers.","metaTitle":"HealthTree Press - HealthTree Myeloma","slug":"healthtree-press","title":"HealthTree Press"},"WSTraX4hOKp92asdiTHa":{"description":"Our HealthTree Programs articles highlight the programs, events, and updates of the HealthTree Foundation.","metaDescription":"These articles highlight the programs, events, and updates of the HealthTree Foundation.","metaTitle":"HealthTree Programs - HealthTree Foundation","slug":"healthtree-programs","title":"HealthTree Programs"},"hUncpyMvyuZCF2qvA0Cv":{"description":"Our Clinical Trials articles highlight top clinical trials, their results, and how patients can participate in them.","metaDescription":"These articles highlight top clinical trials, their results, and how patients can participate in them.","metaTitle":"Clinical Trials - HealthTree Foundation","slug":"clinical-trials","title":"Clinical Trials"},"haqKTOi9lG4MNU3rNLG6":{"description":"Our Treatment Advances articles cover treatment option updates, new combinations of treatments, FDA approval news, and more.","metaDescription":"It's important for patients to stay up-to-speed on advancements in their cancer because the treatment options are rapidly changing.","metaTitle":"Treatment Advances - HealthTree Foundation","slug":"treatment-advances","title":"Treatment Advances"},"hn1DyzeAyX6tgl3gxSDx":{"description":"Our Navigating Your Health articles can help you proactively take control of your health through wellness news, financial updates, healthy recipes, and more.","metaDescription":"Learn tips related to your overall wellness, including your mental, physical, and emotional health.","metaTitle":"Navigating Your Health - HealthTree Foundation","slug":"navigating-your-health","title":"Navigating Your Health"},"j4bWXiDzhdlhMFvaeXoc":{"description":"Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.","metaDescription":"These articles discuss the latest coverage of medical advancements from recent academic conferences.","metaTitle":"Conferences - HealthTree Foundation","slug":"conferences","title":"Conferences"}},"categoryIdBySlug":{"clinical-trials":"hUncpyMvyuZCF2qvA0Cv","conferences":"j4bWXiDzhdlhMFvaeXoc","core-education":"MB3xw38fuKkx0LdszsrL","healthtree-press":"SOL2ODcbaDI1CazQRbRS","healthtree-programs":"WSTraX4hOKp92asdiTHa","navigating-your-health":"hn1DyzeAyX6tgl3gxSDx","patient-stories":"19hxT6XALz8ds00eORms","research":"BnXIg7Ru4SK5FpscX41b","treatment-advances":"haqKTOi9lG4MNU3rNLG6"},"defaultMetaDescription":"These articles are about HealthTree's progress in major media publications in video, online and in newspapers.","defaultMetaTitle":"HealthTree Press - HealthTree Myeloma","lastQueriedDoc":null,"reachedEnd":true,"trendingArticlesForWidget":[{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/dtN24frUcPS1CRElyXh1"},"categories":[{"_type":"DocumentReference","path":"apps/community/articleCategories/WEPsQuvYm62UR7vv8fW1"}],"category":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"createdAt":{"_type":"Date","value":"Thu Feb 22 2024 16:30:39 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/cll"}],"headerImageUrl":"https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2Fshutterstock_1911958477_79662d94-8a1f-4dbc-953e-91836368e8e5.jpg?alt=media","htmlContent":"

What is Beta-2 Microglobulin?

\n\n

Beta-2 microglobulin (B2M) is a cell surface protein that checks for cancer cell growth. It’s known as a tumor marker; it indicates that the cell is inflamed or performing abnormally. It can be found in blood or urine, and its discovery can indicate different diseases.

\n\n

When CLL cells replicate, they release B2M into the blood. Doctors use the B2M test to assess the number of cancer cells in the body and their growth rate, and it also helps determine the response to treatment.

\n\n

Are There Other Conditions That Affect B2M Levels?

\n\n

Apart from leukemia and other types of cancer, B2M levels may be altered for patients with kidney disease, HIV/AIDS, and some autoimmune diseases. B2M can be found in the cerebral spinal fluid in some neurological disorders like multiple sclerosis.

\n\n

How Does the B2M Test Work?

\n\n

The test relevant for CLL measures the concentration of B2M protein in the blood through a simple blood test. A healthcare professional will draw a blood sample, usually from a vein in your arm. The sample will be sent to a laboratory for analysis. Each lab may have a different B2M normal value range when reporting your results.

\n\n

B2M can be found in other samples, such as urine, which is used mostly to evaluate specific kidney disorders. In rarer cases, a cerebrospinal fluid sample is extracted to test B2M in patients with neurological disorders. However, the blood sample version is the most commonly used method for blood cancer patients.

\n\n

Do I Need to Prepare for the B2M Test?

\n\n

No special preparation is usually required for the B2M blood test. However, if you have any questions, consult your doctor.

\n\n

How Long Will It Take to Recieve My B2M Results?

\n\n

The time frame to receive the results of your B2M test can vary depending on the laboratory and healthcare facility. Typically, results are available within a few days, but it can sometimes take up to a week. Your healthcare provider will inform you when to expect the results and how they will be communicated.

\n\n

What Do My B2M Test Results Mean?

\n\n

A healthcare professional familiar with your medical history and CLL should interpret your B2M test results. Here are some basic aspects of the B2M test so that you can understand what the test's values mean if you receive your results before your doctor.

\n\n

B2M blood sample: \n\n\t
- Normal range: The normal range of B2M in the blood is usually between 1.5 to 3 mg/L. This may vary slightly between laboratories.
- Elevated levels: Higher levels of B2M in your blood may indicate more advanced CLL.
\n\t
B2M urine sample: \n\t
- Normal range: The normal range of B2M in a urine sample is usually between 0.04 to 0.22 mg/L.
- Elevated levels: Higher levels of B2M in a urine sample indicate that there might be a condition impacting your kidneys.
\n\t

\n\n

In conclusion, the B2M test is helpful for monitoring chronic lymphocytic leukemia. By assessing how much of the B2M protein is in your blood (and/or urine), your doctor can interpret CLL progression. This information helps your doctor make informed decisions regarding your treatment.

\n\n

To be up-to-date with CLL news, conferences, and treatment advances, you can subscribe to the HealthTree for CLL newsletter!

\n\n

SUBSCRIBE TO CLL NEWSLETTER

\n\n

Source:

\n\n

Beta2 microglobulin

\n","language":"EN","metaDescription":"Doctors use the beta-2 microglobulin (B2M) test to assess how much cancer is in your body and how fast it is growing. Learn more about this important protein!","metaTitle":"What Happens if My Beta-2 Microglobulin is High?","migratedReason":"global-community","migratedReason2":"fix global-community categories","oldAuthor":{"_type":"DocumentReference","path":"apps/community/authors/xByWWvI42oUh3A80DUjH"},"oldCategory":{"_type":"DocumentReference","path":"apps/community/categories/vbpzOatbyE6mGIYm4MSH"},"publishedAt":{"_type":"Date","value":"Thu Aug 29 2024 04:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"What does it mean when your beta-2 microglobulin is high, chronic lymphocytic leukemia, cll, cll cancer, cll leukemia, lymphocytic leukemia, chronic leukemia, small lymphocytic lymphoma, sll, cll sll, cll/sll, cll news, cll disease, b cll, cll Beta-2 Microglobulin, cll Beta-2, cll Microglobulin test, cll Microglobulin, cll B2M test, cll B2M meaning, B2M cll, leukemia disease, cll cancer, cll, leukemia cll, cll lymphocyte, chronic lymphocytic leukemia symptoms, cll cancer symptoms, cll symptoms, lymphocytic leukemia symptoms, chronic leukemia symptoms, blood test for leukemia, how is leukemia detected, B2M, beta 2 microglobulin, understanding my labs, what b2 microglobulin means","slug":"tests-for-cll-patients-beta-2-microglobulin","status":"ACTIVE","title":"What is the Beta-2 Microglobulin Test for CLL?","updatedAt":{"_type":"Date","value":"Wed Aug 21 2024 23:18:30 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/MxcUerwoytKnCf6JDYgB"},"snapshot":{"exists":true,"id":"MxcUerwoytKnCf6JDYgB","ref":{"_type":"DocumentReference","path":"apps/community/articles/MxcUerwoytKnCf6JDYgB"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/NRcFf0ATixvpHmsyX2JM"},"category":{"_type":"DocumentReference","path":"apps/community/categories/j4bWXiDzhdlhMFvaeXoc"},"createdAt":{"_type":"Date","value":"Wed Nov 13 2024 20:48:11 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/non-hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/b-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fvaccines_d131bb76-a251-4e24-8c80-e131e7b68697.jpg%253Falt%253Dmedia","htmlContent":"

The results of a new study showed how hypogammaglobulinemia is being tested and treated in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Patients receiving IVIG are less likely to experience severe infections; however, IgG testing is not as common as expected in the real world.

The press release shared important insights from the study and featured Dr. Jacob D. Soumerai, MD, assistant professor of medicine at Massachusetts General Hospital Cancer Center and Harvard Medical School, and the study’s lead investigator.

“This is the first large, real-world study to examine current practices in IgG testing and the use of image-guided radiation therapy among patients with CLL and NHL,” said Dr. Soumerai

They studied the medical records of 17,192 adult patients treated for CLL (3,960) or non-Hodgkin lymphoma (13,232, ~70% diagnosed with B-cell lymphoma) between 2010 and 2023.

51.2% of non-Hodgkin lymphoma patients underwent IgG testing and 4.7% received Immunoglobulin replacement therapy (IgRT)
67% of CLL patients received IgG testing, and 6.5% were treated with IgRT.

What is immunoglobulin replacement therapy IgRT?

Immunoglobulin G (IgG) specifically, is an antibody found in blood plasma. Low counts of IgG can lead to immune deficiencies and immunoglobulin replacement therapy can help these patients have better immune responses.

IgRT is used to boost IgG levels and help patients overcome infections. However, many patients do not receive regular IgG monitoring at diagnosis, before treatments that can cause hypogammaglobulinemia (like rituximab or obinutuzumab), or after infections.

Routine IgG testing (which measures the immunoglobins G in blood) is rare. There is a lack of consistency in guidelines regarding the timing and frequency of IgG testing, the definition of hypogammaglobulinemia, and when to start IgRT. This study aimed to analyze IgG testing patterns and evaluate the effectiveness of IgRT in reducing infections for CLL and non-Hodgkin lymphoma patients.

What are the Study’s Findings?

The study examined patients with at least one IgG test, comparing IgG levels, infection rates, and antibiotic use at three, six, and 12 months before and after receiving IgRT.

Dr. Soumerai’s team discovered that increased IgG testing is linked to a much lower risk of developing severe infections. Specifically, 86% of non-Hodgkin lymphoma patients and 92% of patients with CLL who had three or more IgG tests had a reduced risk of severe infection.

When assessing IgG levels before and after IgRT initiation, they found a significantly lower number (~20% reduction) of patients with hypogammaglobulinemia after 3, 6, and 12 months. This translated into a lower number of infections and a lower number of patients who needed antimicrobial medication just 3 months after starting IgRT, demonstrating the utility of IVIG to restore the levels of IgG in both CLL and NHL.

“This underlines the urgent need to establish clear consensus on best practices for IgG testing and IgRT use in patients with CLL and NHL, to reduce recurrent infections in our patients,” Dr. Soumerai said.

Final Thoughts

The advantage of a retrospective study is that it analyzes on a greater scale what factors can contribute to improving patient outcomes. Although the sample is large, the minorities are underrepresented since most of the patients in the registry were white, and the study only included patients treated in the Mass General Brigham health care system.

Larger studies are needed to confirm the optimum process for IgG testing and the timing of immunoglobulin replacement therapy for all patient groups to prevent serious infections in more patients.

Learn more from HealthTree’s free webinars!

If you are interested in learning more about CLL and lymphoma, you can participate in our free webinars, where experts answer your questions! Don’t miss our latest webinar: “Caring for the Caregiver: Effective Stress Management Strategies”

Sources:

","language":"EN","metaDescription":"New study shows IVIG replacement lowers infection risk in CLL and NHL patients, highlighting the need for better IgG testing and IgRT guidelines.","metaTitle":"IVIG Reduces Infections in CLL and NHL Patients","publishedAt":{"_type":"Date","value":"Fri Nov 15 2024 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":" IVIG, CLL, non-Hodgkin lymphoma,NHL, ASH, infections, IgG testing, hypogammaglobulinemia, IgRT, cancer treatment, antibody replacement, infection prevention","slug":"real-world-results-preventing-infections-ivig-igrt","status":"ACTIVE","title":"Real-world Results for Preventing Infections in CLL and Non-Hodgkin Lymphoma Patients","updatedAt":{"_type":"Date","value":"Wed Nov 13 2024 21:12:27 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/VRUtF5Ot2k0qceapt5VU"},"snapshot":{"exists":true,"id":"VRUtF5Ot2k0qceapt5VU","ref":{"_type":"DocumentReference","path":"apps/community/articles/VRUtF5Ot2k0qceapt5VU"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/dtN24frUcPS1CRElyXh1"},"category":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"createdAt":{"_type":"Date","value":"Wed Nov 13 2024 21:19:16 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/cll"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252FScreen%252520Shot%2525202024-10-23%252520at%25252011.06.13%252520AM_419d3d31-bef8-4a39-9909-29725d1ada5b.png%253Falt%253Dmedia","htmlContent":"

CLL specialists often talk about how the first-generation BTK inhibitor ibrutinib (Imbruvica, Janssen Biotech) has worse heart-related side effects like atrial fibrillation than next-generation BTK inhibitors zanubrutinib (Brukinsa, BeiGene), acalabrutinib (Calquence, AstraZeneca) and pirtobrutinib (Jaypirca, Eli Lilly).

Researchers conducted a study to examine the heart-related side effects of BTK inhibitors more in-depth. Learn how BTK inhibitors may impact heart health in people with chronic lymphocytic leukemia (CLL) and ways to manage these side effects.

What are the Heart-Related Side Effects of BTK Inhibitors?

Some of the potential side effects of BTK inhibitors are irregular heartbeats called arrhythmias. One of the types of arrhythmias is called atrial fibrillation, as it affects the upper chambers of the heart.

In atrial fibrillation, the nodes of the heart that send electrical pulses to set its pace are irregular and too fast. This can cause blood to pool in the heart’s chamber, allowing blood clots to form. These blood clots can travel to areas like the brain, potentially causing a stroke.

$\"\"$

(Image source: Shutterstock)

Treatments for atrial fibrillation help regulate the heart’s pace to reduce the risk of stroke or death. If properly treated, atrial fibrillation is not usually life-threatening.

If you experience symptoms of atrial fibrillation like irregular and fast heartbeat, lightheadedness, extreme fatigue, shortness of breath, or chest pain, contact your doctor, who can help you meet with a heart specialist called a cardiologist. They will conduct tests like an electrocardiogram (ECG) to monitor heart arrhythmias and create a treatment plan to manage the condition.

How Many CLL Patients Developed Heart Arrhythmias on BTK Inhibitors?

Researchers evaluated electrocardiogram (ECG) results of 98 CLL patients who had been taking a BTK inhibitor for an average of 34 months. 61.2% of the patients were taking ibrutinib. The other 38.8% were taking a next-generation BTK inhibitor (zanubrutinib, acalabrutinib, or pirtobrutinib). 36% of the patients taking a next-generation BTK inhibitor had previously taken ibrutinib and then switched. 27.6% of patients had experienced a prior heart arrhythmia before starting a BTK inhibitor. At the time of testing, up to 20% of patients were already taking heart medication like beta-blockers or calcium channel blockers to manage an arrhythmia.

At the time of the ECG test:

72.4% of CLL patients had a heart arrhythmia\n
- 16.3% of these were new cases of atrial fibrillation. Patients had a greater chance of developing atrial fibrillation if they took ibrutinib instead of next-generation BTK inhibitors.
- 14.3% were ventricular tachycardia (the heart’s lower chambers beat quickly in a coordinated way, preventing the heart from pumping enough blood to the body’s tissues).
- 31.6% were SVTs (supraventricular tachycardia, an irregularly fast heartbeat caused by altered electrical signaling in the heart. It is usually harmless and doesn’t last long. If SVTs continue to occur, they can develop into atrial fibrillation).
\n

After the new diagnosis, CLL patients who took heart arrhythmia treatments saw an improvement in the condition.

Why Do BTK Inhibitors Cause Heart Issues?

In the case of ibrutinib, researchers believe it causes heart arrhythmias because of off-target effects. This means that instead of only inhibiting the BTK molecule to limit CLL progression, it also impacts other molecules in the body, like C-terminal Src kinase (CSK), which helps regulate your heartbeat.

Other reasons why BTK inhibitors may impact heart health are thought to be related to increasing inflammation, thickening of heart valves, and damage to the heart wall’s muscles.

It’s important to note that the risk of developing heart arrhythmias increases with age. They are especially common for people over the age of 60. It is possible you may have had an arrhythmia before starting a BTK inhibitor.

If you develop a heart arrhythmia during treatment with a BTK inhibitor, your CLL specialist may recommend reducing the dose. They may also suggest adding a heart arrhythmia medication or choosing a different CLL treatment altogether.

Summary

A study showed that for CLL patients who had taken BTK inhibitors for an average of 34 months, 72.4% of them had irregular heartbeats (called arrhythmias) when evaluated by an electrocardiogram (ECG) test. The specific types of arrhythmias included atrial fibrillation, ventricular tachycardia, and supraventricular tachycardia. Patients who took ibrutinib over next-generation BTK inhibitors were more likely to develop atrial fibrillation. Medicines that treat arrhythmias help manage patients' heart conditions. Please talk to your CLL specialist if you have any concerns regarding heart health while taking a BTK inhibitor.

Track your CLL Labs

Interested in keeping track of your CLL labs in one place? Click on the link below to access your free account!

Track My CLL Labs

!AD!

Sources:

","language":"EN","metaDescription":"Learn how BTK inhibitors may impact heart health in people with chronic lymphocytic leukemia (CLL) and ways to manage these side effects.","metaTitle":"BTK Inhibitors for CLL Impact on Heart Health","publishedAt":{"_type":"Date","value":"Wed Nov 13 2024 07:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"BTK inhibitors side effects, managing CLL heart risks, atrial fibrillation CLL treatment, heart arrhythmia in CLL patients, ibrutinib heart issues, next-generation BTK inhibitors side effects, chronic lymphocytic leukemia heart health, atrial fibrillation management, ECG for CLL patients, CLL BTK inhibitor comparison, Afib BTK inhibitor, Afib CLL, healthtree, CLL news, chronic lymphocytic leukemia, small lymphocytic lymphoma, cll sll, sll","slug":"heart-health-impact-btk-inhibitors-cll","status":"ACTIVE","title":"How Can BTK Inhibitors for CLL Impact Your Heart Health?","updatedAt":{"_type":"Date","value":"Wed Nov 13 2024 21:49:14 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/uNT92M3W8cOG5xdjAjDF"},"snapshot":{"exists":true,"id":"uNT92M3W8cOG5xdjAjDF","ref":{"_type":"DocumentReference","path":"apps/community/articles/uNT92M3W8cOG5xdjAjDF"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/dtN24frUcPS1CRElyXh1"},"categories":[{"_type":"DocumentReference","path":"apps/community/articleCategories/WEPsQuvYm62UR7vv8fW1"}],"category":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"createdAt":{"_type":"Date","value":"Sat Mar 04 2023 16:48:54 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/cll"}],"headerImageUrl":"https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2Fshutterstock_1907869414_53229ac5-0f16-4a05-a7d2-41067826159d.jpg?alt=media","htmlContent":"

What is oxidative stress, and how does it impact cancer-killing immune system cells? Learn answers to these questions and more below!

How Do Immune System Cells Lose Their Power to Fight Cancer?

In healthy individuals, certain immune system cells like T cells and natural killer (NK) cells have the capability to kill cancer cells. In people with cancer, these cells often stop being effective at killing cancer as they show signs of exhaustion.

Dr. Santosha Vardhana from Memorial Sloan Kettering Cancer Center (MSK) found that immune system cell exhaustion is caused by oxidative stress and is reversible with antioxidants. When oxidative stress is high, it negatively impacts cells’ mitochondria, limiting their ability to produce energy and keep immune system cells working properly.

When antioxidants were administered, they reversed the mitochondrial damage, keeping the immune system cells working well to continue killing cancer cells.

What is Oxidative Stress?

Oxidative stress refers to an imbalance of too many free radicals (unpaired electrons) and not enough antioxidants to neutralize them. If free radicals are not neutralized with antioxidants, they remain chaotically unpaired, damaging parts of the body. Over time, oxidative stress is the underlying condition that contributes to chronic inflammation, insulin resistance, diabetes, and cardiovascular disease.

Free radicals are a normal byproduct of certain body processes. However, they can be produced in excess under certain conditions (please see the next section for these instances).

Your body naturally produces antioxidants like glutathione in the liver and has the capability to balance free radicals to a certain extent. The issue arises when there becomes an imbalance of too many sources causing high amounts of free radicals and not enough antioxidants to neutralize them. To balance this, additional antioxidants are needed, such as through nutrition, and measures need to be taken to reduce external sources of oxidative stress.

What are the Sources of Oxidative Stress?

There are various sources that can cause a buildup of free radicals and not enough antioxidants to neutralize them (referred to as oxidative stress). Some of them include:

Sleep deprivation
Excess psychological stress
Excess intense exercise\n
- \"Antioxidant defenses are sufficient to meet an increase in free radical production during low-intensity exercise, but as exercise-intensity increases, these defenses are surpassed, resulting in significant oxidative stress\" -Aspetar Sports Medicine Journal
\n
Certain viruses like COVID-19\n
- Over time, the oxidative stress buildup leads to high inflammation and chronic fatigue. Reducing oxidative stress with antioxidants can help reduce cellular fatigue
\n
Foods that, during the refining process, strip the food of their natural antioxidants, causing excess free radicals to be produced when they are metabolized\n
- Examples include refined carbohydrates and refined sugars. To reduce excess oxidative stress, swap with whole grain flour and cane sugar. These contain natural antioxidants that help balance your body’s redox state (the balance between antioxidants and free radicals)
\n
Artificial sweeteners like aspartame
Meats cured with nitrates and nitrites
Excess iron consumption
Imbalance of too much copper and not enough zinc (click here to read how your home’s plumbing may affect this and strategies to manage)
Cigarette smoke
Alcohol
Herbicides and pesticides
Radiation
Pollution
Intake of harmful metals like lead, mercury, and aluminum

How Can I Reduce Oxidative Stress?

You may not have control over all sources of oxidative stress; however, listed below are foods and spices with the highest antioxidant capacity that are proven to reduce excess free radicals.

If your oxidative stress level (sometimes referred to as your redox balance) has been too high for a long period of time, it may have damaged your liver’s ability to make enough of its own antioxidant glutathione. Studies have shown that it takes about three months of consistent supplemental antioxidant therapy to keep free radical levels low enough that your body can repair and improve its ability to make antioxidants well again.

Measuring Antioxidant Levels in Food/Spices

The antioxidant level in food is measured using the Oxygen Radical Absorbance Capacity (ORAC) value.

\n
“ORAC value uses the \"total antioxidant capacity\" of a food by placing a sample of the food in a test tube, along with certain molecules that generate free radical activity and certain other molecules that are vulnerable to oxidation. After a while, they measured how well the sample protected the vulnerable molecules from oxidation by the free radicals. The less free radical damage there is, the higher the antioxidant capacity of the test substance” (ORAC value).
\n

Here is a list of foods and spices with high ORAC values (spice list is per 100g):

$\"\"$

Some blood cancer patients from HealthTree have reported trying the highest antioxidant spice clove powder packed into capsules to improve their redox balance. You can either make the capsules yourself or purchase them from an online retailer such as here.

Patients have also suggested defrosting a few cups of wild blueberries (found in the freezer section next to regular blueberries) and immersion blending with a little water for a high-antioxidant sweet drink.

Is it Safe for Cancer Patients to Use Antioxidant Therapy?

In slow-growing (chronic) cancers, reducing sources of inflammation like oxidative stress may be a safe way of improving treatment effectiveness. Click here to learn more. Antioxidants may support these patients and be safe to help cells undergo apoptosis, a process in which cells self-recognize that they are damaged and self-destruct if they are unable to repair themselves.

In fast-growing (acute) cancers, it may be safest to wait to introduce high-antioxidant foods/spices to your diet after your standard cancer treatment helps you achieve remission. This is because antioxidants de-exhaust all cells, including cancer cells. It may not be safe to de-exhaust your body’s microenvironment while waiting for your cancer-killing immune system cells to play catch-up, which may allow aggressive cancer cells to spread even faster.

Further research is needed to help identify the best timing for this. Additional strategies being tried include pairing antioxidant therapy with cellular therapies to help empower the re-engineered immune system cells and avoid exhaustion, as seen in a clinical trial at MSK for lymphoma patients. Similar trials using this strategy may support other patients receiving cellular therapies like CAR-T.

Protect Healthy Cells From Free Radical Damage

Reducing excess oxidative stress by increasing antioxidant consumption helps protect healthy cells and their DNA. High amounts of free radicals for long periods of time may damage cells' DNA. If the free radicals happen to damage part of the DNA that contains instructions to repair DNA, suppress tumors, or tell cells beyond repair to die, then the cell is left with damaged instructions that could then allow the ineffective mutated cell to keep multiplying (cancer cell).

Summary

Reducing free radical buildup with supplemental antioxidants may help your immune system cells effectively kill cancer cells and avoid exhaustion. It is likely safest to try this at-home approach once in remission following standard cancer treatment. Additional research is needed to evaluate strategies to combine antioxidants with cellular therapies to support treatments like CAR-T for reducing T-cell exhaustion.

!AD!

Sources:

","language":"EN","metaDescription":"What is oxidative stress, and how does it impact cancer-killing immune system cells? Learn answers to these questions!","metaTitle":"Oxidative Stress Impact on Immune System Cells","migratedReason":"global-community","migratedReason2":"fix global-community categories","oldAuthor":{"_type":"DocumentReference","path":"apps/community/authors/xByWWvI42oUh3A80DUjH"},"oldCategory":{"_type":"DocumentReference","path":"apps/community/categories/vbpzOatbyE6mGIYm4MSH"},"publishedAt":{"_type":"Date","value":"Fri Nov 01 2024 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"CLL what to eat, CLL nutrition, cll antioxidants, what to eat with chronic lymphocytic leukemia, how to increase immune system with cll, decrease cll fatigue, cure cancer, cll decrease fatigue","slug":"cll-patients-strengthen-t-cells-with-antioxidants","status":"ACTIVE","title":"How Do Oxidative Stress and Antioxidants Impact Immune System Cells?","updatedAt":{"_type":"Date","value":"Tue Nov 12 2024 15:39:16 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/zCneykX4bdimrAoih15d"},"snapshot":{"exists":true,"id":"zCneykX4bdimrAoih15d","ref":{"_type":"DocumentReference","path":"apps/community/articles/zCneykX4bdimrAoih15d"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/dtN24frUcPS1CRElyXh1"},"categories":[{"_type":"DocumentReference","path":"apps/community/articleCategories/WEPsQuvYm62UR7vv8fW1"}],"category":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"createdAt":{"_type":"Date","value":"Mon Mar 27 2023 16:15:42 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/cll"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fshutterstock_515346742_b1114003-8034-402f-90d0-43bcece9bac1.jpg%253Falt%253Dmedia","htmlContent":"

A complete blood count is a standard test part of everyone’s annual checkup. How does this test differ for people with chronic lymphocytic leukemia (CLL)? How do you interpret your test results? Learn answers to these questions and more below.

Complete Blood Count (CBC) for CLL

A complete blood count (CBC) is a test that reviews the number of blood cells in a sample using a specialized machine. If there is anything abnormal, the person evaluating the results, called a pathologist, may also look at the sample under a microscope. The test evaluates the number of:

\n
White blood cells, also called leukocytes, help fight infections
\n
\n
Red blood cells, also called erythrocytes, help carry oxygen to parts of the body
\n
- \n
  Hemoglobin is a protein in red blood cells that carries oxygen
  \n
- \n
  Hematocrit is the percentage of red blood cells in a sample
  \n
\n
\n
Platelets, also called thrombocytes, help clot blood
\n

As CLL affects a type of white blood cell, an additional test called “differential” is added to the CBC to examine the specific types of white blood cells.

$\"\"$

Complete Blood Count with Differential Meaning

If your CBC test shows elevated white blood cells, a differential will likely be added to specifically evaluate which white blood cell type is high.

White blood cell types include basophils, neutrophils, eosinophils, monocytes, and lymphocytes. CLL affects B-cell lymphocytes, or B-cells for short.

If the number of lymphocytes (also referred to as your lymphocyte “count”) is elevated, additional testing like those listed here will be conducted to confirm a CLL diagnosis. To review what normal blood count ranges are, please see below.

CLL cells become elevated because they don’t die when they should, which can crowd out other types of blood cells. CLL treatments can help manage the cancer over time.

$\"\"$

Complete Blood Count Results for CLL

Interested in keeping track of your CLL labs in one place? Click on the link below to access your free account! Doing so will help you see everything in one place and easily flag any values out of range.

Track My CLL Labs

Once you have your CBC test results, how do you interpret them? What is considered a normal range of blood counts?

Normal blood count ranges as measured in cells per liter (cells/L) or grams per deciliter (grams/dL) include:

Red blood cell (RBC)\n
- Male: 4.35 trillion to 5.65 trillion cells/L
- Female: 3.92 trillion to 5.13 trillion cells/L
\n
Hemoglobin (Hb)\n
- Male: 13.2 to 16.6 grams/dL (132 to 166 grams/L)
- Female: 11.6 to 15 grams/dL (116 to 150 grams/L)
\n
Hematocrit (Hct)\n
- Male: 38.3% to 48.6%
- Female: 35.5% to 44.9%
\n
Platelet count (PLT)\n
- Male: 135 billion to 317 billion/L
- Female: 157 billion to 371 billion/L
\n
White blood cell (WBC)\n
- Male or female: 3.4 billion to 9.6 billion cells/L
\n

Normal ranges for individual types of white blood cell counts from the differential portion of the test are measured by microliter (μl or mcL) or cubic millimeter (mm3) of blood. These include:

\n
Neutrophils (NEUT): 2,500-8,000 per microliter (μl) (55-70% of blood)
\n
\n
Lymphocytes (LYMPH): 1,000-4,000 per μl (20–40%)
\n
\n
Monocytes (MONO): 100-700 per μl (2–8%)
\n
\n
Eosinophils (EOS): 50-500 per μl (1–4%)
\n
\n
Basophils (BASO): 25-100 per μl (0.5-1%)
\n

Each facility may have slightly different variations of normal values.

Once additional tests confirm the increased lymphocytes are CLL, a diagnosis of CLL is made if the lymphocyte count is over 5,000 cells per microliter (μl) of blood.

If the lymphocyte count is not yet over 5,000 cells per microliter but other tests have confirmed that the B-cells are cancerous, it is referred to as CLL’s pre-condition monoclonal B-cell lymphocytosis (MBL).

If you have a confirmed diagnosis of CLL, click here to learn about when you may need treatment.

Can Sources Other than Cancer Cause Blood Counts to be Abnormal?

Apart from cancer, there are various reasons that can account for an increase or decrease in your blood counts. These may include conditions like active infections, exposure to chemicals, autoimmune disorders, nutrition deficiencies, and more. Consult with your doctor about other areas that may be affecting your blood counts.

Summary

A complete blood count (CBC) with a differential test helps provide people with CLL information about the status of their blood cell counts. This information can assist patients and their healthcare team in monitoring the cancer’s status over time and provide insight that may influence treatment decisions.

!AD!

Sources:

","language":"EN","metaDescription":"A complete blood count is standard in checkups. How does it vary for CLL? Learn how to interpret your results below.","metaTitle":"CLL Patient Tests - Complete Blood Count (CBC)","migratedReason":"global-community","migratedReason2":"fix global-community categories","oldAuthor":{"_type":"DocumentReference","path":"apps/community/authors/xByWWvI42oUh3A80DUjH"},"oldCategory":{"_type":"DocumentReference","path":"apps/community/categories/vbpzOatbyE6mGIYm4MSH"},"publishedAt":{"_type":"Date","value":"Tue Oct 15 2024 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"CBC test for CLL, Understanding CLL blood counts, Differential blood count in CLL, White blood cell count for CLL, Normal blood count ranges CLL, CLL lymphocyte count interpretation, What does high WBC mean in CLL?, CLL blood test results explained, Complete Blood Count with Differential meaning, Signs of CLL in blood test, Cbc cll, cll cbc results, cll cbc report, cll cbc profile, cll cbc findings, what blood tests show cll, chronic lymphocytic leukemia cbc results, cll sll, sll, small lymphocytic lymphoma, healthtree ","slug":"tests-for-cll-patients-complete-blood-count","status":"ACTIVE","title":"What is a Complete Blood Count (CBC) Test for CLL?","updatedAt":{"_type":"Date","value":"Tue Oct 29 2024 21:11:57 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/ziurKFtPMjd90FFbmM1f"},"snapshot":{"exists":true,"id":"ziurKFtPMjd90FFbmM1f","ref":{"_type":"DocumentReference","path":"apps/community/articles/ziurKFtPMjd90FFbmM1f"}}}],"upcomingEventsForWidget":[{"data":{"agendaSchedule":[{"agendaPanelist":{"_type":"DocumentReference","path":"apps/community/eventPanelists/dUFWSB1c5zT9gIWAUZmM"},"blockDateTime":{"day":"1","time":{"hours":"3","meridiem":"PM","minutes":"00"}},"description":"

Dalton introduces the agenda of the event and featured speaker Erin Parry, MD, PhD

","id":"list_0684c4b6_7399_44df_ae9b_3708e553e90f","title":"Introduction"},{"agendaPanelist":{"_type":"DocumentReference","path":"apps/community/eventPanelists/34DBpbVt3JZxk8biWMWP"},"blockDateTime":{"day":"1","time":{"hours":"3","meridiem":"PM","minutes":"05"}},"customSpeaker":false,"description":"

Dr. Erin Parry shares about richter syndrome for chronic lymphocytic leukemia patients

","id":"list_1afb18eb_356f_4f08_b277_4945a003d430","title":"Presentation"},{"agendaPanelist":{"_type":"DocumentReference","path":"apps/community/eventPanelists/1qsySl7Sob7U37xHr1M4"},"blockDateTime":{"day":"1","time":{"hours":"3","meridiem":"PM","minutes":"35"}},"description":"

Type your questions in the chat, and Dr. Jacobs will answer them!

\n","id":"list_8ce37376_927e_47c3_838e_2a5392f63811","title":"Questions and Answers"}],"attendeesReminder":[0,1,24],"category":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"chapter":{"_type":"DocumentReference","path":"apps/community/chapters/L658UpLlAr0epzTxv737"},"createdAt":{"_type":"Date","value":"Tue Aug 13 2024 17:48:57 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/cll"}],"endDate":{"datetime":{"_type":"Date","value":"Wed Nov 20 2024 21:00:00 GMT+0000 (Coordinated Universal Time)"},"timezone":"America/New_York"},"eventManager":{"_type":"DocumentReference","path":"users/zSJP9G3GQoOG4DMXkFm6Vt3qOwo1"},"eventRecap":[{"id":"list_f5ee3711_d0cf_427b_a05f_74cbbe2b721d","recapContent":"

Dr. Jacobs starts by discussing what Phase I, II and III trials are.

\n\n

Phase I- Early trial testing safety and some efficacy testing

\n\n

Phase II- More patients enrolled to better study efficacy

\n\n

Phase III- Trial trying to get a treatment approved, these are larger studies that are trying to evaluate if a proposed treatment is better than the standard of care

\n","title":"Phase I, Phase II, Phase III "},{"id":"list_d35fcbd6_888a_4aec_89a4_039572250a8b","recapContent":"

Learn from Dr. Jacobs about some recently finished and ongoing Phase III trials, including the MAJIC Study, which evaluates combining the BTK inhibitor acalabrutinib with the BCL2 inhibitor venetoclax.

\n\n

Dr. Jacobs also discusses the Phase III CELESTIAL study which evaluates the combination of a new BCL2 inhibitor sonrotoclax with the BTK inhibitor zanubrutinib

\n","title":"Phase III Clinical Trials"},{"id":"list_abed3b85_3080_4e13_8a06_f4df64a0a4c8","recapContent":"

Dr. Jacobs talks about a Phase I study evaluating a next-generation BCL2 inhibitor that looks to improve on venetoclax. ABBV- 453

\n\n

Additionally, Dr. Jacobs talks about a Phase I study exploring a new type of therapeutic, the BTK degrader BGB-16673

\n","title":"Phase I Clinical Trials "},{"id":"list_8aac4257_e129_452e_a86c_288939e00a0c","recapContent":"

Some questions asked include:

Do clinical trials cost money for patients?

Any trials or updates for epcortimab?

Is the MAJIC study looking at treatment-naive or relapsed/refractory CLL?

","title":"Q&A"}],"eventRecapHeader":"Event Highlights ","eventRecapStatus":"DRAFT","eventType":"ZOOM_MEETING","headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fendocrinology%252520doctor%252520examining%252520senior%252520woman%252520thyroid_9f67a9de-98a8-463b-b8a6-0399deb29c16.jpg%253Falt%253Dmedia","htmlDescription":"

Richter syndrome, or Richter transformation, is a rare but serious transformation of chronic lymphocytic leukemia to a more aggressive lymphoma. Join us for this virtual webinar with Dr. Erin Parry, a hematologist oncologist specializing in treating and researching chronic lymphocytic leukemia and lymphomas.

","intercomTagName":"Event: 11-20-2024 - Chronic Lymphocytic Leukemia - What Chronic Lymphocytic Leukemia Patients Should Know about Richter Syndrome with Erin Parry, MD, PhD","maxAttendees":0,"metaDescription":"Join Dr. Erin Parry in a webinar on Richter syndrome, the aggressive transformation of chronic lymphocytic leukemia into lymphoma","metaTitle":"Chronic Lymphocytic Leukemia and Richter Syndrome","panelistSpeakers":[{"id":"list_51af1448_6b14_4113_b50e_2fc640cabec6","panelist":{"_type":"DocumentReference","path":"apps/community/eventPanelists/34DBpbVt3JZxk8biWMWP"}},{"id":"list_5aacf771_73b0_44e4_ac62_49dfa1af2cad","panelist":{"_type":"DocumentReference","path":"apps/community/eventPanelists/dUFWSB1c5zT9gIWAUZmM"}}],"publishedAt":{"_type":"Date","value":"Sat Aug 10 2024 07:00:00 GMT+0000 (Coordinated Universal Time)"},"recorded":true,"recordingType":"PUBLIC","sentEventAvailableEmail":false,"slug":"nov2024-chronic-leukemia-richter-syndrome","startDate":{"datetime":{"_type":"Date","value":"Wed Nov 20 2024 20:00:00 GMT+0000 (Coordinated Universal Time)"},"timezone":"America/New_York"},"status":"ACTIVE","title":"What Chronic Lymphocytic Leukemia Patients Should Know about Richter Syndrome with Erin Parry, MD, PhD","totalEventAttendees":49,"totalInPersonAttendees":0,"totalVirtualAttendees":0,"updatedAt":{"_type":"Date","value":"Mon Oct 21 2024 18:53:41 GMT+0000 (Coordinated Universal Time)"},"zoomJoinUrl":"https://us06web.zoom.us/j/82478839179","zoomMeetingId":82478839179,"zoomStartUrl":"https://us06web.zoom.us/s/82478839179?zak=eyJ0eXAiOiJKV1QiLCJzdiI6IjAwMDAwMSIsInptX3NrbSI6InptX28ybSIsImFsZyI6IkhTMjU2In0.eyJpc3MiOiJ3ZWIiLCJjbHQiOjAsIm1udW0iOiI4MjQ3ODgzOTE3OSIsImF1ZCI6ImNsaWVudHNtIiwidWlkIjoiUDhOc3V2dVlUXzZrSGtLbWZnTEZDdyIsInppZCI6IjRhOGM5MDRhMzkwMzQ4OTE4NDEzZWU2MTM4NjFlYTY5Iiwic2siOiIwIiwic3R5IjoxMDAsIndjZCI6InVzMDYiLCJleHAiOjE3Mjk1NDM2OTksImlhdCI6MTcyOTUzNjQ5OSwiYWlkIjoiVnEwc0ZHTUlTTmFxMVpqN3QyZ3ZWQSIsImNpZCI6IiJ9.z1a6-OgnlwNtLqd5Zm7_FzkiMHCLAMLL8PbrDhUwL9U"},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/events/WLtzHAZMkl9CsN2vK68W"},"snapshot":{"exists":true,"id":"WLtzHAZMkl9CsN2vK68W","ref":{"_type":"DocumentReference","path":"apps/community/events/WLtzHAZMkl9CsN2vK68W"}}}]}